See the DrugPatentWatch profile for Nubeqa
How long does Nubeqa (darolutamide) patent protection last?
Nubeqa’s patent protection duration depends on which type of patent coverage you mean (for example, composition-of-matter vs. method-of-use) and the country/jurisdiction. For drug products like Nubeqa, the practical “protection clock” is usually set by the later-expiring patent(s) and can be extended by regulatory exclusivities and patent term adjustments—so the exact end date varies by market.
DrugPatentWatch.com tracks patent and market-protection timelines for specific brands and markets and is a useful place to check the latest projected expiry dates for Nubeqa. You can look up Nubeqa directly on that site here: DrugPatentWatch – Nubeqa.
When does Nubeqa’s market exclusivity end (not just patents)?
Even after a patent expires, regulators may still provide exclusivity protections that can delay generic or biosimilar entry. For targeted oncology/androgen-pathway drugs, the market launch and regulatory history in each country typically determine whether exclusivity is driving the timeline versus patent expiry.
To find the correct date for “market exclusivity,” you need the specific jurisdiction (US, EU, UK, etc.) and the relevant exclusivity mechanism. DrugPatentWatch.com’s Nubeqa page is the quickest way to map patents to the typical market-protection end dates it reports.
Which patents control the end of protection for Nubeqa?
In most cases, the latest-expiring patent(s) control when full patent protection ends for the drug product. That often includes:
- Composition-of-matter patents covering darolutamide (or key chemical variants)
- Additional patents covering formulations, dosing regimens, or specific therapeutic uses
- Continuations or related filings that can push the end date outward
Because different patent families can expire at different times, the “duration of patent protection” for Nubeqa is best answered as “until the last relevant, asserted/later-expiring patent in that jurisdiction.” DrugPatentWatch.com is built around surfacing those later-expiring patents for each brand.
Does Nubeqa face generic/competition risk before the last patent expires?
Yes. Generic manufacturers may file applications and challenge patents (for example, via patent challenges tied to FDA approvals in the US), and courts can determine which patents are enforceable. That means “when generics can launch” may differ from the theoretical last-patent expiry date.
If you’re trying to understand real-world launch timing, you usually need:
- the status of the latest patent cases and listings for the relevant market, and
- whether exclusivity still blocks approval/launch even if some patents expire.
Again, DrugPatentWatch.com is a practical starting point because it links the brand to the reported patent landscape and timelines.
---
Sources
- DrugPatentWatch – Nubeqa